Journal
NANOMEDICINE
Volume 18, Issue 10, Pages 819-831Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2023-0015
Keywords
liposomes; lung cancer; multidrug resistance; P-glycoprotein antibody conjugated; paclitaxel
Ask authors/readers for more resources
This study aimed to overcome the resistance of lung cancer cells to paclitaxel by preparing P-glycoprotein antibody-conjugated paclitaxel PEG-coated immunoliposomes (Pab-PTX-L). The results showed that Pab-PTX-L had nano-sized particles with high encapsulation efficiency of paclitaxel and exhibited better cellular uptake, cell viability inhibition, and apoptosis induction in paclitaxel-resistant lung cancer cells. Moreover, Pab-PTX-L demonstrated good tumor-targeting and antitumor effects in mouse experiments.
Aims: To overcome the resistance of lung cancer to paclitaxel. Methods: P-glycoprotein antibody-conjugated paclitaxel PEG-coated immunoliposomes (Pab-PTX-L) were prepared, and a series of quality evaluations, in vitro cell evaluation and assessment of their in vivo antitumor effect in mice were conducted. Results: The results showed that Pab-PTX-L was nano-sized with high encapsulation efficiency of paclitaxel. For the paclitaxel-resistant lung cancer A549/T cells, the cellular uptake and cell viability inhibition and apoptosis of Pab-PTX-L-treated cells were higher than those of the control groups. More importantly, Pab-PTX-L showed a good targeting and antitumor effect on tumor tissue in mouse experiments. Conclusion: This study will provide a new insight on enhanced paclitaxel delivery into paclitaxel-resistant cancer cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available